The vaccine candidate NVX-CoV2373 has demonstrated clinical efficacy against the original Covid-19 strain and both of the rapidly emerging variants in the UK and South Africa.
Novavax, Serum Institute plans to supply 1.1 billion doses to COVAX
Novavax has signed a memorandum of understanding (MoU) in this regard with Gavi, the Vaccine Alliance.
 "Vaccine")
Premium
The vaccine doses of NVX-CoV2373 will be manufactured and distributed globally by SII and Novavax.
The vaccine candidate NVX-CoV2373 has demonstrated clinical efficacy against the original Covid-19 strain and both of the rapidly emerging variants in the UK and South Africa.
First Published: Feb 19 2021 | 11:12 PM IST
Key stories on business-standard.com are available only to BS Premium subscribers.
Register to read more on Business-Standard.com
